Prosthetic valve endocarditis: clinical findings and management
View abstract on PubMed
Summary
This summary is machine-generated.Prosthetic valve endocarditis (PVE) affects 1.4% early and 1.5% late after surgery. Surgical treatment significantly improves survival rates compared to conservative management for PVE patients.
Area Of Science
- Cardiology
- Infectious Diseases
- Surgical Innovation
Background
- Prosthetic valve endocarditis (PVE) is a serious complication following prosthetic heart valve implantation.
- Understanding the incidence, causative agents, and clinical manifestations of PVE is crucial for patient outcomes.
Purpose Of The Study
- To investigate the incidence, microbiology, clinical presentation, and treatment outcomes of prosthetic valve endocarditis.
- To compare survival rates between conservative and surgical management strategies for PVE.
Main Methods
- Retrospective analysis of 46 patients diagnosed with PVE out of 2163 patients with prosthetic heart valves.
- Microbiological analysis to identify causative pathogens.
- Echocardiographic and fluoroscopic assessments for valve dysfunction.
- Comparison of survival rates based on treatment modality (conservative vs. medical plus surgical).
Main Results
- Cumulative PVE rates were 1.4% early and 1.5% between 60 days and 10 years post-surgery.
- Staphylococci (37%), streptococci (20%), and Gram-negative species (13%) were common pathogens; fungi (9%) and mixed infections (21%) also noted.
- Early PVE showed a higher incidence of staphylococci, Gram-negative pathogens, and fungi.
- Surgical intervention significantly improved 6-month survival (66%) versus conservative treatment (31%) and long-term survival (51% vs. 15%).
- Factors predicting worse prognosis included heart failure, persistent sepsis, septic embolism, and renal failure.
Conclusions
- Prosthetic valve endocarditis requires prompt diagnosis and management.
- Surgical treatment offers a significantly better prognosis than conservative management for PVE.
- Early valve re-replacement demonstrates a more favorable outcome in specific patient subgroups.